Today marks a major milestone for Everest Medicines (HKEX 1952.HK, “Everest”) with the successful launch of XERAVA® (eravacycline) in China. The first prescription of XERAVA® was written and issued at the renowned Huashan Hospital affiliated to Fudan University. This momentous occasion signals Everest’s transition into a commercial-stage biopharmaceutical company dedicated to developing, manufacturing, and commercializing cutting-edge medicines and vaccines.
XERAVA® (eravacycline) is the revolutionary new fluorocycline antibiotic for treating infections caused by susceptible infections caused by both gram-positive, gram-negative and anaerobic bacteria, including difficult-to-treat MDR isolates.
Approved in March 2023 by the Chinese National Medical Products Administration for the treatment of complicated intra-abdominal infections, XERAVA® has since been broadly recommended by numerous treatment guidelines as the go-to solution for bacterial infection due to its powerful bacteria-fighting activity and broad bacterial spectrum coverage.
Everest Medicines has reached a major milestone with the successful launch of XERAVA® in China! CEO Rogers Yongqing Luo expressed great appreciation to all involved in making this achievement possible and announced plans to expedite access to XERAVA® with a lean commercial team.
He also expressed ambition to further advance approval and commercialization of other first-in-class or best-in-class drug candidates such as Nefecon, in order to meet urgent unmet needs in China and beyond.
Dr. Zhu Duming, leader and chief physician of the Critical Care Department at Zhongshan Hospital Affiliated with Fudan University, has welcomed the launch of eravacycline in China. With its broad antibacterial spectrum and high potency against common clinical multi-drug resistant bacteria such as ESBL-producing bacteria, CRE, CRAB, MRSA and VRE, eravacycline is equipped to help doctors combat the difficulties of clinically-resistant diseases.
Even more, the powerful antibiotic has been recommended by authoritative guidelines worldwide for the treatment of MDR Gram-negative bacterial infections.
Eravacycline, the world’s first fluorocycline antibiotic, has proven to be a revolutionary innovative choice for the treatment of MDR/CRO infections that carry unnaturally high mortality rates for patients with neutropenia and fever suffering from malignant hematological diseases. This is thanks to comprehensive Phase II/III clinical trials and real-world studies, which demonstrate that eravacycline offers good clinical efficacy and safety profiles.
As such, antibacterial treatment is increasingly becoming more important for this type of patient. According to Sun Aining, Chief Physician at the First Affiliated Hospital of Soochow University, eravacycline stands out as a reliable and highly effective treatment option.
About XERAVA® (eravacycline)
XERAVA®, a fully synthetic, fluorocycline intravenous antibiotic, is helping to fight infections caused by drug-resistant bacteria, including MDR strains. Approved for use in the US, EU, GB, Singapore, mainland China, Hong Kong and currently under review for cIAI in Taiwan, XERAVA® is making a real difference in the treatment of complicated intra-abdominal infections. Licensed from Tetraphase Pharmaceuticals, Inc., a subsidiary of Innoviva, Inc., XERAVA® is transforming the way we treat resistant infections.
About Everest Medicines
Everest Medicines is a biopharmaceutical game-changer with a commitment to develop, manufacture and market life-saving pharmaceutical products and vaccines that fill critical unmet health needs in Asia. Our experienced team of experts have extensive backgrounds from leading global and Chinese pharmaceutical companies in disciplines such as drug discovery, clinical research, regulatory affairs, CMC, business operations, and beyond.
We’ve built a portfolio centered around core areas such as renal diseases, infectious diseases, and autoimmune disorders pushing the boundaries of what’s possible with potentially first-in-class or best-in-class molecules.